title: Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man.
abstract: OBJECTIVE
  Following intravenous administration of its prodrug, L-758,298, we assessed the pharmacodynamics of L-754,030, a novel and highly selective NK1 receptor antagonist, by examining systemic haemodynamics and the blood flow responses to intra-arterial substance P infusion.
  
  
  METHODS
  Sixteen healthy male volunteers participated in a double-blind, randomised, placebo controlled crossover trial of L-758 298. Forearm blood flow was measured using venous occlusion plethysmography during intrabrachial substance P infusion (0.125-128 pmol min-1 ). In part 1, eight subjects received substance P infusions before and during placebo, 0.25 mg, 1 mg or 5 mg of L-758 298. In part 2, eight subjects received substance P infusions 24 h after placebo or 1.43 mg of L-758 298.
  
  
  RESULTS
  L-758 298 caused dose dependent inhibition of substance P induced vasodilatation (P<0.001). Placebo adjusted differences (95% CI) in baseline forearm blood flow, mean arterial pressure and heart rate showed no relevant changes with 5 mg of L-758 298 (>1400-fold shift in substance P response): 0.00 (-0.49 to +0.49) ml 100 ml-1 min-1, 1. 0 (-3.2 to +5.2) mmHg and 1.9 (-5.9 to +9.7) beats min-1, respectively. Twenty-four hours after 1.43 mg of L-758,298, there was approximately 34-fold shift in response to substance P induced vasodilatation (P<0.008) at plasma L-754 030 concentrations of 2-3 ng ml-1. L-758 298 was generally well tolerated without serious adverse events.
  
  
  CONCLUSIONS
  Substance P induced forearm vasodilatation is mediated by the endothelial cell NK1 receptor in man but endogenous substance P does not appear to contribute to the maintenance of peripheral vascular tone or systemic blood pressure.
authors.affiliation: Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, Scotland, UK. D.E.Newby@ed.ac.uk
authors.forename: D E
authors.initials: DE
authors.lastname: Newby
authors.forename: D G
authors.initials: DG
authors.lastname: Sciberras
authors.forename: C J
authors.initials: CJ
authors.lastname: Ferro
authors.forename: B J
authors.initials: BJ
authors.lastname: Gertz
authors.forename: D
authors.initials: D
authors.lastname: Sommerville
authors.forename: A
authors.initials: A
authors.lastname: Majumdar
authors.forename: R C
authors.initials: RC
authors.lastname: Lowry
authors.forename: D J
authors.initials: DJ
authors.lastname: Webb
mesh_terms: D000080:Acetals / Q000009:adverse effects / Q000494:pharmacology*; D000932:Antiemetics / Q000009:adverse effects / Q000494:pharmacology; D000077608:Aprepitant; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D005542:Forearm / Q000502:physiology; D006801:Humans; D008297:Male; D009025:Morpholines / Q000009:adverse effects / Q000494:pharmacology*; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*; D012039:Regional Blood Flow / Q000187:drug effects; D013373:Substance P / Q000009:adverse effects / Q000494:pharmacology*; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D000080:Acetals; D000932:Antiemetics; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D000077608:Aprepitant; D013373:Substance P